Consistent with its role in inhibiting multiple tumor cellular phenotypes, SCORT‐CasRx‐pre‐gHoxB13 treatment downregulates several oncogenic pathways and upregulates multiple tumor suppressive gene pathways in AR+ CRPC tumors (Figure 6). Here, AR is linked to neoplasm.